

# An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)

Guidance on an additional COVID-19 booster dose in  
the spring of 2023 for individuals at high risk of severe  
illness due to COVID-19

Published: March 3, 2023

PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH



Public Health  
Agency of Canada

Agence de la santé  
publique du Canada

Canada

**TO PROMOTE AND PROTECT THE HEALTH OF CANADIANS THROUGH LEADERSHIP,  
PARTNERSHIP, INNOVATION AND ACTION IN PUBLIC HEALTH.**

— Public Health Agency of Canada

Également disponible en français sous le titre :

Directives sur une dose de rappel supplémentaire du vaccin contre la COVID-19 au printemps 2023 pour les personnes présentant un risque élevé de maladie sévère due à la COVID-19

To obtain additional information, please contact:

Public Health Agency of Canada  
Address Locator 0900C2  
Ottawa, ON K1A 0K9  
Tel.: 613-957-2991  
Toll free: 1-866-225-0709  
Fax: 613-941-5366  
TTY: 1-800-465-7735  
E-mail: [publications-publications@hc-sc.gc.ca](mailto:publications-publications@hc-sc.gc.ca)

© His Majesty the King in Right of Canada, as represented by the Minister of Health, 2023

Publication date: March 2023

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat.: HP5-157/1-2023E-PDF

ISBN: 978-0-660-47815-9

Pub.: 220791

# Preamble

The National Advisory Committee on Immunization (NACI) is an External Advisory Body that provides the Public Health Agency of Canada (PHAC) with independent, ongoing and timely medical, scientific, and public health advice in response to questions from PHAC relating to immunization.

In addition to burden of disease and vaccine characteristics, PHAC has expanded the mandate of NACI to include the systematic consideration of programmatic factors in developing evidence based recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels.

The additional factors to be systematically considered by NACI include: economics, ethics, equity, feasibility, and acceptability. Not all NACI statements will require in-depth analyses of all programmatic factors. While systematic consideration of programmatic factors will be conducted using evidence-informed tools to identify distinct issues that could impact decision-making for recommendation development, only distinct issues identified as being specific to the vaccine or vaccine-preventable disease will be included.

This statement contains NACI's independent advice and recommendations, which are based upon the best current available scientific knowledge. This document is being disseminated for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph. Recommendations for use and other information set out herein may differ from that set out in the product monographs of the Canadian manufacturers of the vaccines. Manufacturer(s) have sought approval of the vaccines and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

# Background

On January 20, 2023, NACI published [Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023](#). This guidance consolidated and reinforced previously established booster dose recommendations and extended the fall booster program for those who had not yet received a 2022 recommended booster dose into 2023.

Since that time:

- Omicron sub-lineages continue to be the dominant strains of COVID-19 circulating in Canada. Viral sequencing is currently showing clear dominance of variants BQ.1 and BQ.1.1, while an increase in the XBB.1.5 recombinant sub-lineage is also being observed. Based on neutralization studies, BQ\* and XBB\* sub-lineages are more immune evasive than earlier sub-lineages (such as BA.2 and BA.5), with XBB\* described as the most immune evasive sub-lineage.
- While there are fluctuations in COVID-19 transmission indicators (i.e., cases reported, hospitalizations, and deaths) and variation across provinces and territories, COVID-19 activity has been relatively stable with hospitalizations remaining at a relatively high level since the widespread circulation of Omicron in early 2022.
- Additional evidence has emerged on the performance and safety of bivalent vaccines, and the duration of protection of vaccination and hybrid immunity which help to inform the need for and benefit of additional booster doses.

NACI continues to monitor the rapidly evolving scientific data recognizing that the trajectory of the COVID-19 pandemic remains unclear. Updated recommendations will be made as needed.

NACI's recommendations remain aligned with the goals of the Canadian COVID-19 Pandemic Response that were last updated on [February 14, 2022](#):

- To minimize serious illness and death while minimizing societal disruption as a result of the COVID-19 pandemic.
- To transition away from the crisis phase towards a more sustainable approach to long term management of COVID-19.

# Methods

On February 6 and 7, 2023, NACI reviewed the available epidemiology and evidence on vaccine protection and hybrid immunity, including the performance of bivalent vaccines based on clinical trial data and real-world evidence from observational studies. Preliminary modelling data were also considered, as were ethics and acceptability considerations. NACI continues to apply the [decision-making framework for booster doses](#) in their deliberations. NACI approved these recommendations on February 19, 2023.

For further information on NACI's recommendations on the use of COVID-19 vaccines, please refer to National Advisory Committee on Immunization (NACI): [Statements and publications](#) and the [COVID-19 vaccine chapter](#) in the [Canadian Immunization Guide](#) (CIG)

Further information on NACI's process and procedures is available elsewhere <sup>(1, 2)</sup>.

# Overview of Evidence

Available information as of February 5, 2023, is summarized below.

## Evolving epidemiology

- The evolutionary trajectory of SARS-CoV-2, including the emergence of novel variants of concern (VOCs), remains uncertain.
- Omicron BQ.1 sub-lineages are currently the dominant strains circulating in Canada, while viral sequencing is also showing increases in the XBB.1.5 recombinant sub-lineage.
- Recently circulating sub-lineages of Omicron (e.g., BQ\*, XBB\*) are more immune evasive than previous sub-lineages (e.g., BA.2, BA.4/5), based on the ability of recent sub-lineages to more efficiently evade neutralizing antibodies elicited from vaccination and past infection<sup>(3-10)</sup>.
- Rates of hospitalizations and deaths in Canada continue to be highest in unvaccinated individuals, particularly for adults 60 years of age and older, with risk increasing with age and highest among those ≥80 years, and lowest for those recently vaccinated<sup>(11)</sup>.
- Seroepidemiologic studies demonstrate high levels of antibodies to vaccines and/or infection in the Canadian population<sup>(12)</sup>.

## Vaccine effectiveness and duration of vaccine protection of mRNA COVID-19 vaccine booster doses

Vaccine protection against infection and symptomatic disease with original monovalent COVID-19 vaccines has been shown to wane over time; however, protection against severe outcomes persists longer than protection against symptomatic disease<sup>(13-24)</sup>. Evidence suggests that a fourth dose of an original monovalent COVID-19 vaccine provides an increase in vaccine effectiveness (VE) against infection; however, waning of protection is observed over time, consistent with the waning of protection after two or three doses<sup>(25-30)</sup>. VE against severe disease from booster doses is generally higher and more sustained than against infection. Due to the short follow-up period to date, there are no estimates available regarding waning following bivalent booster doses against infection or severe disease.

- Real-world effectiveness data from the US suggest that in adults, a booster dose of a BA.4/5 bivalent mRNA COVID-19 vaccine provides increased protection against both symptomatic disease and hospitalization, compared to those who did not receive a bivalent booster dose but received at least 2 previous doses of original monovalent vaccines in the past<sup>(31, 32)</sup>. The relative VE of the bivalent booster increased with increased time since the original vaccine group received their last dose, due to increased waning over time in this group. From these observational studies, it cannot be determined if the benefit is due to the recent receipt of a booster dose and/or specifically the receipt of a bivalent booster.
- Other clinical data comparing relative VE from a bivalent booster dose to an original monovalent booster dose are emerging. Although there are some limitations in these studies (often including earlier receipt of an original booster than a bivalent booster), the emerging evidence suggests that the bivalent vaccine performs at least as well as, and possibly better than, the original vaccine against circulating strains.

- Two recent studies by Lin et al. used linked administrative data from North Carolina to provide evidence regarding the VE of bivalent BA.4/5 booster doses compared to original monovalent booster doses.
  - The first study of individuals  $\geq 12$  years of age assessed relative VE against severe outcomes of a single booster dose (original or bivalent BA.4/5, manufacturer not specified) compared to a previous original vaccine dose (primary series, or a first or second booster dose) during a period of 15-99 days after the booster dose. A single BA.4/5 bivalent mRNA booster dose provided greater and somewhat more sustained relative protection against severe outcomes than the relative protection from a single original mRNA booster dose. However, the original booster was administered and assessed over a three-month period occurring earlier than that of the bivalent booster, and other factors such as circulating variants and the extent of previous infection may have been different between the groups <sup>(33)</sup>.
  - The second study (preprint) of children 5 to 11 years of age found that the relative VE against infection of a booster dose compared to only receiving two previous original vaccine doses was higher for those who received the BA.4/5 bivalent vaccine (manufacturer not specified) as a booster than the original vaccine as a booster. However, like the previous study, the original vaccine was given during an earlier period than the bivalent vaccine. As well, in some instances, the third dose may have been part of a 3-dose primary series recommended for immunocompromised individuals instead of a booster dose, and the distribution of those who are immunocompromised may have differed between the groups <sup>(34)</sup>.
- Preliminary data from Ontario that was presented to NACI demonstrates that short-term (<90 days) VE against severe outcomes in community dwelling adults aged  $\geq 50$  years was similar between those receiving original and bivalent mRNA vaccine booster doses and between the available vaccine products (Moderna Spikevax original or BA.1 bivalent and Pfizer-BioNTech Comirnaty original or BA.4/5 bivalent) during a period when BA.5 was the predominant Omicron sub-lineage and BQ.1 was emerging <sup>(35)</sup>.
- Preliminary data (preprint) from four Scandinavian countries used linked administrative data to evaluate the VE of a fourth dose (either original, BA.1 bivalent or BA.4/5 bivalent) up to 60 days after receipt of the booster dose relative to a third original vaccine dose. Regardless of product received, a fourth dose was associated with significantly reduced risks of hospitalization and death, compared to receiving only three doses. There was a trend towards increased protection against severe outcomes associated with a fourth dose of bivalent vaccine compared to a fourth dose of original vaccine, however effect estimates were imprecise with wide confidence intervals (CI) <sup>(36)</sup>. When comparing the BA.1 bivalent and BA.4/5 bivalent vaccines (manufacturer not specified), the BA.4/5 bivalent vaccine was associated with a somewhat lower relative risk of hospitalization compared to the BA.1 bivalent vaccine. However, this observation was based primarily on the comparative VE from Denmark. The VE estimate was not significant for Norway, and not estimable in the other two countries.
- A randomized clinical trial conducted by Moderna in the United Kingdom (preprint) compared those  $\geq 16$  years of age randomized to receive a bivalent BA.1 booster to those randomized to receive an original monovalent booster. Although the primary endpoint was immunogenicity, exploratory analyses revealed that the

efficacy against symptomatic disease was somewhat higher for the bivalent booster than the original booster against sub-lineages BA.2 (relative VE of bivalent booster compared to original booster vaccine of 32.6%; 95% CI: -15.1 to 60.5%) and BA.4 (41.6%; 95% CI: -5.1 to 67.5%), but not against BA.5 (4.4%; 95% CI: -27.2 to 28.2%)<sup>(37)</sup>.

- VE and duration of protection are still emerging for more recent variants (i.e., XBB.1.5 and BQ.1).
  - A recent US study compared relative VE against symptomatic disease in immunocompetent adults who had and had not received a bivalent BA.4/5 booster among those who had previously received 2 to 4 original monovalent vaccine doses. Relative VE for the bivalent vaccine booster compared to past monovalent doses for at least 3 months after bivalent vaccination ranged from 37% to 52% (with somewhat lower VE with increasing age) against Omicron subvariants which were determined likely XBB/XBB.1.5-related and ranged from 40 to 49% against likely BA.5-related strains based on S-gene target status. The relative VE estimates for the bivalent BA.4/5 vaccine against XBB/XBB.1.5-related and BA.5-related strains were similar<sup>(38)</sup>.
  - There are currently no available data regarding bivalent vaccine protection against severe disease caused by XBB/XBB.1.5.

## Safety of Omicron-containing bivalent mRNA COVID-19 vaccines

- Available evidence from Canada and internationally show that overall, the safety profile of the bivalent mRNA COVID-19 vaccine boosters is comparable to that of original mRNA COVID-19 vaccine boosters among individuals aged  $\geq 5$  years<sup>(39-45)</sup>.
- The safety profile appears to be similar in those with or without previous SARS-CoV-2 infections.
- A possible association between Pfizer-BioNTech Comirnaty bivalent BA.4/5 booster and ischemic stroke in persons  $\geq 65$  years of age has been identified by the US Vaccine Safety Datalink (VSD)<sup>(46, 47)</sup>. This possible association has not been replicated in other surveillance systems used to monitor vaccine safety in the US or in other countries. As well, this potential safety signal has not been identified with the Moderna Spikevax bivalent BA.4/5 mRNA COVID-19 vaccine. To date, the totality of the US data suggests that it is very unlikely that the potential signal in VSD represents a true clinical risk<sup>(46-48)</sup>. This is supported by international data including from Canada, Israel, Europe, and Singapore where a similar signal has not been identified. Monitoring of the potential safety signal is ongoing. NACI updates its recommendations as needed.

## Hybrid immunity

- Hybrid immunity results from  $\geq 1$  exposure(s) from vaccination and  $\geq 1$  exposure(s) from SARS-CoV-2 infection (before or after vaccination). Previous infection and vaccination may provide superior protection (as measured by neutralization capacity) against VOCs, including Omicron, compared with primary vaccination only, or previous SARS-CoV-2 infection without vaccination.
- In Canada, hybrid immunity population profiles differ by age group. A greater proportion of older adults are protected by vaccination only and have not been infected, as compared to younger ages. Adolescents and young adults have the highest proportion of hybrid immunity, and a large proportion of children have been infected but not vaccinated<sup>(12)</sup>.

- There are Canadian data suggesting that vaccine protection may reach a plateau for adults with hybrid immunity, with limited benefit demonstrated in receiving booster doses of the original mRNA COVID-19 vaccines against Omicron subvariants BA.2 infection/symptomatic disease in healthcare workers with hybrid immunity and against BA.1, BA.2 and BA.4/5 hospitalization in non-institutionalized elderly populations with hybrid immunity <sup>(15, 49, 50)</sup>. Additionally, VE is lower in adults without previous infection and has more pronounced waning over time compared to those with previous infection.
- A systematic review and meta-regression study also found that protection against severe disease from hybrid immunity with primary series vaccination remained >95% until the end of available follow-up at 11 months after vaccination and up to 4 months based on available data from hybrid immunity with first booster vaccination. Based on statistical modelling projections, protection from hybrid immunity would be sustained at elevated levels to at least 12 months after primary series and at least 6 months after booster vaccination <sup>(51)</sup>. However, the analysis was based on studies on protection conferred by pre-Omicron SARS-CoV-2 strains and there was no consideration of the impact on protection due to circulation of more immune evasive Omicron subvariants.
- These data suggest that future booster program efforts may achieve the greatest impact among those who have not yet been infected by the SARS-CoV-2 virus. Further study will be needed to determine whether the findings regarding the protection from hybrid immunity would apply broadly to Omicron-containing bivalent COVID-19 vaccines (although based on available evidence regarding the performance of bivalent vaccines, this is expected to be the case) and against new subvariants and VOCs.

## **Ethics, equity, feasibility, and acceptability (EEFA)**

- Given the considerable uncertainty regarding the trajectory of the COVID-19 pandemic, NACI based its recommendations on an evidence-informed framework and recommends booster doses focused on those at greatest risk of severe illness from COVID-19 at this time.
- COVID-19 vaccine uptake increases with age in Canada, but uptake with each subsequent dose has decreased suggesting acceptability has decreased over time.
- There may be variability in how each province, territory and community assesses risk and responds to the needs of their respective jurisdictions.
- Supply of bivalent vaccines (BA.1 or BA.4/5) in Canada is expected to be sufficient to accommodate NACI's recommendations for booster doses.

## **Other considerations**

- Using assumptions based on recent VE studies, where waning protection against hospitalisations occurs most in older adults without hybrid immunity, modelling suggests that an additional booster dose in adults 65 years and older starting this spring could be expected to prevent hundreds or thousands of hospitalizations across the country this year if a booster dose restores protection to levels achieved shortly after the previous dose. Modelled estimates are dependent on various assumptions on aspects such as the durability of protection from bivalent booster doses, the rate of infection of future subvariants, and the ability of future subvariants to escape protection offered by the vaccines.



# Recommendations

Please see [Table 1](#) for an explanation of strong versus discretionary NACI recommendations.

NACI continues to recommend a COVID-19 vaccine primary series as follows:

1. Individuals 5 years of age and older should be immunized with a primary series of an authorized mRNA vaccine. (*Strong NACI recommendation*)
2. Children 6 months to under 5 years of age may be immunized with a primary series of an authorized mRNA vaccine. (*Discretionary NACI recommendation*)

Additional details including those pertaining to alternative vaccine products are available in the [COVID-19 vaccine chapter](#) in the Canadian Immunization Guide and NACI [statements and publications](#).

3. For individuals who have not received previously recommended doses (primary series or booster doses, including the fall 2022 booster dose), NACI recommendations are available in [Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023](#).
4. **Starting in the spring of 2023, NACI recommends that an additional booster dose may be offered as per the recommended interval\* to the following individuals who are at increased risk of severe illness from COVID-19:**
  - Adults 80 years of age and older
  - Adult residents of long-term care homes and other congregate living settings for seniors or those with complex medical care needs
  - Adults 18 years of age and older who are [moderately to severely immunocompromised](#) (due to an underlying condition or treatment)
  - Adults 65 to 79 years of age, particularly if they do not have a known prior history of SARS-CoV-2 infection\*\*

### ***(Discretionary NACI recommendation)***

\* The recommended interval is 6 or more months from the last COVID-19 vaccine dose or SARS-CoV-2 infection if applicable (whichever is longer). It should be noted that vaccination with shorter intervals between previous vaccination or infection has not been shown to pose a safety risk, though evidence shows that the antibody response is higher with longer intervals between infection and vaccination and with longer intervals between vaccination doses.

\*\*Previous infection can be defined in different ways based on jurisdictional policies and access to testing. The following suggestion can be considered to define previous infection with SARS-CoV-2:

- Confirmed by a molecular (e.g., PCR) or Health Canada-approved antigen detection-based test; or
  - Symptomatic disease compatible with COVID-19 AND household exposure to a confirmed COVID-19 case.
- Bivalent Omicron-containing mRNA COVID-19 vaccines are the preferred booster products.
  - No other recommendations for additional booster doses are being made at this time.

- NACI will continue to monitor the SARS-CoV-2 epidemiology and emerging evidence, including duration of vaccine protection from bivalent booster doses in the coming months to provide recommendations on the timing of subsequent booster doses if warranted.
- Planning should consider that vaccine deployment may be recommended for broader population groups in the fall of 2023 depending on the COVID-19 pandemic context.

For further information on these recommendations, please refer to the [COVID-19 vaccine chapter](#) in the [Canadian Immunization Guide](#) (CIG).

NACI continues to monitor and assess the evidence as it emerges and will update its recommendations as needed.

## RESEARCH PRIORITIES

1. Continuous monitoring of data on the safety, immunogenicity, efficacy, and effectiveness of COVID-19 vaccines, including bivalent mRNA booster doses, through clinical trials and studies in real-world settings, including the degree and duration of protection conferred by each booster dose against circulating variants. The research should also consider the clinical implications of previous SARS-CoV-2 infection; repeated immunization; and outcomes after any infection such as multisystem inflammatory syndrome in children (MIS-C), post-COVID-19 condition/post-acute COVID syndrome (long COVID), or infection-induced myocarditis and/or pericarditis in older adult, adult, adolescent, and pediatric populations.
2. Further evaluations of the optimal interval between dose administration, as well as further evaluations of the optimal interval between previous SARS-CoV-2 infection and vaccine dose administration.
3. Vigilant monitoring and reporting of adverse events of special interest to support the rapid identification of potential vaccine safety signals and accurately inform potential risks associated with any future booster doses. Global collaboration should be prioritized to enable data sharing so decision makers around the world can weigh benefits and risks of additional booster doses of COVID-19 vaccines.
4. Continuous monitoring of COVID-19 epidemiology and VE in special populations at high risk of severe outcomes or long-term consequences of infection with COVID-19, including but not limited to those with co-morbidities, immunocompromising conditions, and pregnant populations.
5. Further evaluation on the optimal timing and trigger for the initiation of potential future booster dose recommendations, as well as evaluation of potential risks associated with providing booster doses earlier than necessary.
6. Continuous monitoring of vaccine coverage in Canada, for COVID-19 vaccines and other routine vaccines, particularly in the context of COVID-19 vaccine booster doses and including consideration of measures that may reduce the risk of disparities in vaccine confidence and uptake across different sub-populations.

**Table 1. Strength of NACI Recommendations**

<b>Strength of NACI recommendation</b> based on factors not isolated to strength of evidence (e.g., public health need)	<b>Strong</b>	<b>Discretionary</b>
<b>Wording</b>	<i>“should/should not be offered”</i>	<i>“may/may not be offered”</i>
<b>Rationale</b>	Known/anticipated advantages outweigh known/anticipated disadvantages (“should”), OR Known/Anticipated disadvantages outweigh known/anticipated advantages (“should not”)	Known/anticipated advantages are closely balanced with known/anticipated disadvantages, OR Uncertainty in the evidence of advantages and disadvantages exists
<b>Implication</b>	A strong recommendation applies to most populations/individuals and should be followed unless a clear and compelling rationale for an alternative approach is present.	A discretionary recommendation may be considered for some populations/individuals in some circumstances. Alternative approaches may be reasonable.

# ACKNOWLEDGMENTS

**This statement was prepared by:** E Wong, B Warshawsky, J Montroy, J Zafack, MC Tunis, R Harrison, S Wilson, and S Deeks, on behalf of NACI.

**NACI gratefully acknowledges the contribution of:** K Ramotar, C Mauviel, M Salvadori, R Krishnan, A Killikelly, E Tice, and the NACI Secretariat.

**NACI members:** S Deeks (Chair), R Harrison (Vice-Chair), M Andrew, J Bettinger, N Brousseau, H Decaluwe, P De Wals, E Dubé, V Dubey, K Hildebrand, K Klein, M O'Driscoll, J Papenburg, A Pham-Huy, B Sander, and S Wilson.

**Liaison representatives:** L Bill / M Nowgesic (Canadian Indigenous Nurses Association), LM Bucci (Canadian Public Health Association), S Buchan (Canadian Association for Immunization Research and Evaluation), E Castillo (Society of Obstetricians and Gynaecologists of Canada), J Comeau (Association of Medical Microbiology and Infectious Disease Canada), M Lavoie (Council of Chief Medical Officers of Health), J MacNeil (Centers for Disease Control and Prevention, United States), D Moore (Canadian Paediatric Society), M Naus (Canadian Immunization Committee), M Osmack (Indigenous Physicians Association of Canada), J Potter (College of Family Physicians of Canada), and A Ung (Canadian Pharmacists Association).

**Ex-officio representatives:** V Beswick-Escanlar (National Defence and the Canadian Armed Forces), E Henry (Centre for Immunization and Respiratory Infectious Diseases (CIRID), PHAC), M Lacroix (Public Health Ethics Consultative Group, PHAC), P Fandja (Marketed Health Products Directorate, Health Canada), D MacDonald (COVID-19 Epidemiology and Surveillance, PHAC), S Ogunnaike-Cooke (CIRID, PHAC), C Pham (Biologic and Radiopharmaceutical Drugs Directorate, Health Canada), M Routledge (National Microbiology Laboratory, PHAC), and T Wong (First Nations and Inuit Health Branch, Indigenous Services Canada).

## **NACI COVID-19 Vaccine Working Group**

**Members:** S Wilson (Chair), M Adurogbangba, M Andrew, Y-G Bui, H Decaluwe, P De Wals, V Dubey, S Hosseini-Moghaddam, M Miller, D Moore, S Oliver, and E Twentyman.

**PHAC Participants:** NK Abraham, O Baclic, L Coward, P Doyon-Plourde, N Forbes, M Hersi, N Islam, SJ Ismail, C Jensen, F Khan, A Killikelly, R Krishnan, SH Lim, N Mohamed, J Montroy, S Pierre, R Pless, M Salvadori, A Stevens, E Tice, A Tuite, MC Tunis, E Wong, R Ximenes, MW Yeung, and J Zafack.

## REFERENCES

1. Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M. Canada's National Advisory Committee on Immunization (NACI): Evidence-based decision-making on vaccines and immunization. *Vaccine*. 2010;28:A58,63. doi: 10.1016/j.vaccine.2010.02.035.
2. Ismail SJ, Hardy K, Tunis MC, Young K, Sicard N, Quach C. A framework for the systematic consideration of ethics, equity, feasibility, and acceptability in vaccine program recommendations. *Vaccine*. 2020 Aug 10;38(36):5861,5876. doi: 10.1016/j.vaccine.2020.05.051.
3. Chalkias S, Whatley J, Eder F, Essink B, Khetan S, Bradley P, et al. Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19. medRxiv. 2022 Dec 13. <https://doi.org/10.1101/2022.12.11.22283166>.
4. Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, et al. Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine. bioRxiv. 2022 Nov 17. <https://doi.org/10.1101/2022.11.17.516898>.
5. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. *Nat Med*. 2022 Dec 6. doi: 10.1038/s41591-022-02162-x.
6. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. *N Engl J Med*. 2023 Jan 12;388(2):183,185. doi: 10.1056/NEJMc2214293.
7. Arora P, Cossmann A, Schulz SR, Ramos GM, Stankov MV, Jäck H, et al. Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. *Lancet Infect Dis*. 2023 Feb;23(2):147,148. doi: 10.1016/S1473-3099(22)00831-3.
8. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell*. 2023 Jan 19;186(2):279,286.e8. doi: 10.1016/j.cell.2022.12.018.
9. Uriu K, Ito J, Zahradnik J, Fujita S, Kosugi Y, Schreiber G, et al. Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant. *Lancet Infect Dis*. 2023 Jan 31:S1473-3099(23)00051-8. doi: 10.1016/S1473-3099(23)00051-8.
10. Qu P, Faraone JN, Evans JP, Zheng Y, Carlin C, Anghelina M, et al. Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants. medRxiv. 2023 Jan 17. doi: <https://doi.org/10.1101/2023.01.16.524244>.
11. Surveillance and Epidemiology Division, Centre for Immunization and Respiratory Infectious Diseases, Infectious Disease Prevention and Control Branch. Data cut-off Dec 18, 2022. Ottawa (ON): Public Health Agency of Canada; 2022 Dec 18.

12. Seroprevalence in Canada. Data cut-off 2022 Dec 31 [Internet]. Montreal (QC): COVID-19 Immunity Task Force (CITF); 2023 Jan [cited 2023 Feb 20]. Available from: <https://www.covid19immunitytaskforce.ca/seroprevalence-in-canada/>.
13. Grewal R, Nguyen L, Buchan SA, Wilson SE, Nasreen S, Austin PC, et al. Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. medRxiv. 2022 Nov 01. <https://doi.org/10.1101/2022.10.31.22281766>.
14. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *N Engl J Med*. 2022 Jul 7;387(1):21,34. doi: 10.1056/NEJMoa2203965.
15. Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, et al. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study. *Lancet Infect Dis*. 2023 Jan;23(1):45,55. doi: 10.1016/S1473-3099(22)00578-3.
16. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, Florentino PTV, Penna GO, Pearce N, et al. Vaccination plus previous infection: protection during the omicron wave in Brazil. *Lancet Infect Dis*. 2022 May 16. doi:10.1016/S1473-3099(22)00288-2.
17. Chin ET, Leidner D, Lamson L, Lucas K, Studdert DM, Goldhaber-Fiebert JD, et al. Protection against Omicron from Vaccination and Previous Infection in a Prison System. *N Engl J Med*. 2022 Nov 10;387(19):1770,1782. doi: 10.1056/NEJMoa2207082.
18. Lind ML, Robertson AJ, Silva J, Warner F, Coppi AC, Price N, et al. Effectiveness of Primary and Booster COVID-19 mRNA Vaccination against Omicron Variant SARS-CoV-2 Infection in People with a Prior SARS-CoV-2 Infection. medRxiv. 2022 Apr 25. <https://doi.org/10.1101/2022.04.19.22274056>.
19. Spreco A, Dahlström Ö, Jöud A, Nordvall D, Fagerström C, Blomqvist E, et al. Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021-2022: A Naturalistic Case-Control Study in Sweden. *Vaccines (Basel)*. 2022 Aug 7;10(8):1273. doi: 10.3390/vaccines10081273.
20. Vicentini M, Venturelli F, Mancuso P, Bisaccia E, Zerbini A, Massari M, et al. Risk of SARS-CoV-2 Reinfection by Vaccination Status, Predominant Variant, and Time from Previous Infection: A Cohort Study in Italy. SSRN. 2022 Jun 09. doi: 10.2139/ssrn.4132329.
21. Veneti L, Berild JD, Wattle SV, Starrfelt J, Greve-Isdahl M, Langlete P, et al. Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022. medRxiv. 2022 Mar 25. <https://doi.org/10.1101/2022.03.24.22272854>.
22. Gram MA, Emborg H, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. *PLoS Med*. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992.

23. De Serres G, Febriani Y, Ouakki M, Talbot D, Gilca R, Deceuninck G, et al. Efficacité du vaccin contre la COVID-19 causée par le variant Omicron au Québec Résultats Préliminaires. INSPQ. 2022 Feb 16. Available in French: <https://www.inspq.gc.ca/covid-19/vaccination/efficacite-omicron>.
24. Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study. *Nat Commun*. 2022 Sep 30;13(1):5736. doi: 10.1038/s41467-022-33378-7.
25. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. *N Engl J Med*. 2022 May 5;386(18):1712,1720. doi: 10.1056/NEJMoa2201570.
26. Gazit S, Saciuk Y, Perez G, Peretz A, Pitzer VE, Patalon T. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. *BMJ*. 2022 May 24;377:e071113. doi: 10.1136/bmj-2022-071113.
27. Grewal R, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada. *medRxiv*. 2022 Sep 01. <https://doi.org/10.1101/2022.09.29.22280526>.
28. Tseng HF, Ackerson BK, Bruxvoort KJ, Sy LS, Tubert JE, Lee GS, et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. *Nat Commun*. 2023 Jan 12;14(1):189. doi: 10.1038/s41467-023-35815-7.
29. Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, et al. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5. *Lancet Infect Dis*. 2022 Dec;22(12):1663,1665. doi: 10.1016/S1473-3099(22)00692-2.
30. Barda N, Canetti M, Gilboa M, Indenboim V, Asraf K, Weiss-Ottolenghi Y, et al. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022. *Euro Surveill*. 2022 Sep;27(39):2200701. doi: 10.2807/1560-7917.ES.2022.27.39.2200701.
31. Tenforde MW, Weber ZA, Natarajan K, Klein NP, Kharbanda AB, Stenehjem E, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. *MMWR Morb Mortal Wkly Rep*. 2022 Dec 30;71(5152):1616,1624. doi: 10.15585/mmwr.mm715152e1.
32. Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde AA, Douin DJ, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022. *MMWR Morb Mortal Wkly Rep*. 2022 Dec 30;71(5152):1625,1630. doi: 10.15585/mmwr.mm715152e2.
33. Lin D, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. *N Engl J Med*. 2023 Jan 25. doi: 10.1056/NEJMc2215471.

34. Lin D, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age. medRxiv. 2023 Jan 19. <https://doi.org/10.1101/2023.01.18.23284739>.
35. Kwong J, CIRN PCN Ontario team. Personal communication. Effectiveness of monovalent and bivalent mRNA COVID-19 vaccine booster doses against Omicron severe outcomes. 2022 Dec 12.
36. Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries. medRxiv. 2023 Jan 19. <https://doi.org/10.1101/2023.01.19.23284764>.
37. Lee IT, Cosgrove CA, Moore P, Bethune C, Nally R, Bula M, et al. A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273. medRxiv. 2023 Jan 24. <https://doi.org/10.1101/2023.01.24.23284869>.
38. Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119,124. doi: 10.15585/mmwr.mm7205e1.
39. Ischaemic stroke following mRNA bivalent COVID-19 vaccination Canada December 1, 2020 - January 6, 2023. [Unpublished]. Ottawa (ON): Public Health Agency of Canada (PHAC); 2023 Jan 18.
40. Lavery I. No 'elevated risk' of stroke from Pfizer's bivalent COVID shot, Health Canada says [Internet]. Global News; 2023 Jan 29 [cited 2023 Feb 02]. Available from: <https://globalnews.ca/news/9443283/covid-pfizer-bivalent-booster-stroke-health-canada/>.
41. Public Health Agency of Canada. Reported side effects following COVID-19 vaccination in Canada. Data cut-off Feb 3, 2023 [Internet]. Ottawa (ON): Health Canada; 2023 Feb 17 [cited 2023 Feb 20]. Available from: <https://health-infobase.canada.ca/covid-19/vaccine-safety/>.
42. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Adverse events following immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to January 29, 2023. Data cut-off Jan 29, 2023 [Internet]. Toronto (ON): King's Printer for Ontario; 2023 Feb 03 [cited 2023 Feb 20]. Available from: [https://www.publichealthontario.ca/-/media/Documents/nCoV/epi/covid-19-aefi-report.pdf?rev=d0854501b255400c927d32857c7b071a&sc\\_lang=en](https://www.publichealthontario.ca/-/media/Documents/nCoV/epi/covid-19-aefi-report.pdf?rev=d0854501b255400c927d32857c7b071a&sc_lang=en).
43. Hause AM, Marquez P, Zhang B, Su JR, Myers TR, Gee J, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023. MMWR Morb Mortal Wkly Rep. 2023 Jan 13;72(2):39,43. doi: 10.15585/mmwr.mm7202a5.
44. Hause AM, Marquez P, Zhang B, Myers TR, Gee J, Su JR, et al. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United



States, August 31–October 23, 2022. *MMWR Morb Mortal Wkly Rep.* 2022 Nov 4;71(44):1401,1406. doi: 10.15585/mmwr.mm7144a3.

45. Andersson NW, Thiesson EM, Vinsløv Hansen J, Hviid A. Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study. *medRxiv.* 2023 Jan 22. <https://doi.org/10.1101/2023.01.21.23284855>.

46. Shimabukuro T, Klein, N. COVID-19 mRNA bivalent booster vaccine safety [slides presented at Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting January 26, 2023] [Internet]. Silver Spring (MD): Food and Drug Administration (FDA); 2023 Jan 26 [cited 2023 Feb 02]. Available from: <https://www.fda.gov/media/164811/download>.

47. CDC & FDA Identify Preliminary COVID-19 Vaccine Safety Signal for Persons Aged 65 Years and Older [Internet]. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2023 Jan 13 [cited 2023 Feb 02]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/bivalent-boosters.html>.

48. Forshee R. Update on Original COVID-19 Vaccine and COVID-19 Vaccine, Bivalent Effectiveness and Safety [slides presented at Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting January 26, 2023] [Internet]. Silver Spring (MD): Food and Drug Administration (FDA); 2023 Jan 26 [cited 2023 Feb 02]. Available from: <https://www.fda.gov/media/164815/download>.

49. Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Fafard J, et al. Prior infection- and/or vaccine-induced protection against Omicron BA.1, BA.2 and BA.4/BA.5-related hospitalisations in older adults: a test-negative case-control study in Quebec, Canada. *medRxiv.* 2022 Dec 27. <https://doi.org/10.1101/2022.12.21.22283740>.

50. Kwong J. Personal communication. 2023 Feb 02.

51. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. *Lancet Infect Dis.* 2023 Jan 18:S1473-3099(22)00801-5. doi: 10.1016/S1473-3099(22)00801-5.